Skip to content

Clinical trials

Renal Insufficiency, Chronic trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Renal Insufficiency, Chronic Phase: Not applicable Country / region: China Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20041
20061
20071
20081
20101
20111
20122
20131
20153
20162
20171
20181
20213
20222
20235
20249
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status17
Completed11
Recruiting9
Terminated3
Not yet recruiting1
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese University of Hong Kong3
Guangdong Provincial People's Hospital2
Hospital Authority, Hong Kong2
Peking Union Medical College Hospital2
Peking University First Hospital2
Peking University People's Hospital2
Shanghai 10th People's Hospital2
The Affiliated Hospital of Xuzhou Medical University2
The Third Xiangya Hospital of Central South University2
Capital Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Renal Insufficiency, Chronic43
Cardiovascular Diseases4
Coronary Artery Disease3
Kidney Diseases3
Kidney Failure, Chronic3
Chronic Disease2
Diabetes Mellitus, Type 22
Hyperuricemia2
Metabolic Syndrome2
Obesity2

Trials

Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.